SonoThera Banks $186M Betting Gene Therapy Can Skip the Virus
San Francisco-based SonoThera has pulled in $186 million from Vida, ARCH, Illumina Ventures, Bayer, J&J and Lilly for a gene therapy platform that leaves the virus out of the delivery step.
SonoThera, a San Francisco gene therapy company led by CEO Kenneth Greenberg and CSO Steve Feinstein, was named an Endpoints 11 2026 winner after raising $186 million from backers including Vida Ventures, ARCH Venture Partners, Illumina Ventures, Leaps by Bayer, Johnson & Johnson Innovation and Eli Lilly.
SonoThera, a privately held gene therapy developer based in San Francisco, has been named one of this year's Endpoints 11 companies — a list of eleven private biotechs singled out by the trade publication — on the strength of a delivery platform that tries to solve gene therapy's oldest bottleneck without using a virus at all.
The company is led by chief executive Kenneth Greenberg and chief scientific officer Steve Feinstein, and has raised $186 million to date. Its cap table reads like a who's who of both specialist life-science funds and corporate strategic money: Vida Ventures, ARCH Venture Partners and Illumina Ventures alongside Leaps by Bayer, Johnson & Johnson Innovation and Eli Lilly. That mix is the tell. Three of the largest drugmakers in the world have put capital behind a delivery idea rather than a single asset.
Why the delivery vehicle, not the gene, is the hard part
Gene therapy's scientific premise has been settled for years: if a disease is caused by a broken or missing gene, supply a working copy. The unsolved engineering problem has always been getting that genetic cargo into the right cells, in enough of them, without triggering the immune system.
The industry's default answer has been the adeno-associated virus, or AAV — a stripped-down virus repurposed as a courier. AAV works, and several approved therapies depend on it. But it carries a familiar set of constraints that anyone who follows the sector can recite: a limited cargo capacity, a manufacturing process that is expensive and difficult to scale, pre-existing immunity in a meaningful share of patients that excludes them from treatment outright, and the practical reality that once a patient has been dosed and has mounted an antibody response, redosing is usually off the table. That last point matters commercially as much as clinically. A one-shot therapy is a one-shot revenue event, and it has to be priced accordingly.
SonoThera's pitch, as described by Endpoints News, is a non-viral route — delivery that does not depend on a viral shell, with ultrasound used to open the door into target tissue. Strip out the virus and, in principle, you strip out the immunity problem, the cargo ceiling and much of the manufacturing burden with it.
What corporate investors are actually buying
Leaps by Bayer, Johnson & Johnson Innovation and Eli Lilly are not venture funds in the ordinary sense. Corporate venture arms invest for optionality: early sight of a platform, a relationship that can convert into a licence or an acquisition, and a hedge against a technology that might otherwise reprice their own pipelines.
For a large pharmaceutical company, a non-viral delivery platform is a horizontal bet. If it works, it is not one drug — it is a route that can be pointed at multiple tissues and multiple genes, and potentially redosed. That is the difference between owning a product and owning a toolkit. It also explains why three separate big-pharma investors can sit on the same cap table without obvious conflict: each may care about a different organ system.
The presence of Illumina Ventures adds another dimension. Sequencing economics and gene therapy economics are linked — cheaper, broader genetic diagnosis expands the addressable patient population for any therapy that corrects a defined mutation. Vida Ventures and ARCH Venture Partners, meanwhile, are among the more concentrated, thesis-driven backers in biotech, and their participation signals conviction rather than index-style exposure.
The $186 million question: how far does it go
A total raise of $186 million is substantial for a private platform company but not unlimited. Gene therapy is among the most capital-intensive corners of drug development, and the costs land early: process development, vector or carrier characterisation, large-animal work, and manufacturing that must be built to regulatory standard long before a pivotal trial begins.
A total raise of $186 million is substantial for a private platform company but not unlimited.
The practical questions for anyone tracking SonoThera from here are the same ones that decide every platform story:
- Human data. Preclinical delivery results are necessary but not sufficient. The industry has seen more than one elegant non-viral approach fail to reproduce animal efficiency in people.
- Tissue selectivity. Which organs the platform can reach, and how precisely, defines the addressable indication list.
- Redosing in practice. The theoretical case for repeat administration without a viral immune response has to be demonstrated, not asserted.
- Manufacturing cost per dose. If non-viral delivery genuinely undercuts AAV production economics, it changes the pricing conversation for an entire class of medicines.
- Partnership structure. Whether the existing corporate investors convert their stakes into formal licensing deals is the clearest external signal of how the technology is performing behind closed doors.
A sector still repairing its credibility
SonoThera's recognition arrives at a point where gene therapy's commercial record has been mixed. Several approved products have reached the market at extraordinary prices and struggled to find the patient volumes to justify the infrastructure built around them. Investor patience for long, capital-hungry preclinical timelines has thinned. Against that backdrop, private financings of this size are a statement about where the remaining conviction sits — in delivery technology rather than in the next individual rare-disease asset.
The broader market gave no particular signal on the day the list was published. The S&P 500, tracked by SPY, closed at $771.35, up 0.54%, with the Nasdaq 100 proxy QQQ at $744.50, up 0.46%, and the Dow tracker DIA at $517.49, up 0.94%, as of the last trade at 20:00 GMT on Sept. 25, 2026. None of that touches a private company directly — SonoThera has no listed shares and no ticker — but it frames the environment in which its backers will eventually decide whether to fund a crossover round, pursue an initial public offering, or sell.
What to watch next
Three developments would materially change the read on SonoThera. The first is any move into clinical development, which would convert a platform narrative into a dataset with a date attached. The second is a named partnership with one of its corporate investors — Bayer, Johnson & Johnson or Lilly — on a specific indication, which would put a third-party valuation on the technology. The third is the size and structure of the next financing round; a large, strategically led raise would suggest the delivery data is holding up, while a bridge would suggest the opposite.
For now, what is on the record is a San Francisco company, two named executives, $186 million in committed capital, a roster of investors with unusually deep pockets, and a thesis that gene therapy's future depends on finally getting past the virus.
Key facts
- Total raised: $186 million to date
- Leadership: Kenneth Greenberg, CEO; Steve Feinstein, CSO
- Corporate backers: Leaps by Bayer, Johnson & Johnson Innovation, Eli Lilly
- Market context: S&P 500 (SPY) closed at $771.35, +0.54%, as of 20:00 GMT Sept. 25, 2026
Frequently asked questions
What does SonoThera do?
SonoThera is a San Francisco-based gene therapy company developing a non-viral approach to delivering genetic material into cells. Rather than relying on an adeno-associated virus as the courier, its platform uses ultrasound-assisted delivery. The company is led by chief executive Kenneth Greenberg and chief scientific officer Steve Feinstein, and has raised $186 million.
Can I buy shares in SonoThera?
No. SonoThera is a privately held company with no listed shares and no exchange ticker. Its $186 million in funding has come from venture and corporate investors including Vida Ventures, ARCH Venture Partners, Illumina Ventures, Leaps by Bayer, Johnson & Johnson Innovation and Eli Lilly. Public exposure would require an initial public offering or an acquisition.
Why does non-viral gene therapy delivery matter?
Viral delivery, chiefly through adeno-associated virus, carries limits: a cap on how much genetic cargo fits, expensive and complex manufacturing, pre-existing immunity that excludes some patients, and an immune response that generally prevents redosing. A non-viral route aims to remove those constraints, potentially widening the eligible patient population and allowing repeat administration.
What is the Endpoints 11?
The Endpoints 11 is an annual list compiled by the trade publication Endpoints News naming eleven private biotechnology companies it considers among the most notable of the year. Selection is editorial recognition rather than a financial transaction, but inclusion often raises a private company's visibility with potential partners, recruits and later-stage investors.
Why are Bayer, J&J and Lilly all invested in the same company?
Corporate venture arms invest for strategic optionality rather than pure financial return. A delivery platform is horizontal technology that can be applied across many genes and tissues, so several large drugmakers can back the same company while targeting different disease areas. Such stakes frequently precede formal licensing agreements or acquisition discussions.
What should investors watch next from SonoThera?
Three markers matter most: entry into clinical trials, which turns a platform story into human data with a timeline; a named licensing deal with one of its corporate investors, which would put an external value on the technology; and the size and structure of the next financing round, which signals how the underlying delivery results are performing.
